MedTrace Logo

A Phase 1 Study of JADE101 in Healthy Participants

NCT07059312 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-12-18

No results posted yet for this study

Summary

This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

JADE101

JADE101 is supplied as sterile solution to be administered by SC injection.

DRUG

Placebo

Placebo solution to be administered at a matching volume by SC injection.

Sponsors & Collaborators

  • Jade Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Li Li, MD · Jade Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-17
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07059312 on ClinicalTrials.gov